Metrion Biosciences Names Drug Discovery and Safety Assessment VP

Metrion Biosciences Ltd., a specialist ion channel contract research and drug discovery company, appointed Steve Jenkinson vice president, drug discovery and safety assessment.

In a statement, the company said that the appointment represents an important step in the expansion of Metrion’s business, driven by its ion channel discovery capabilities.

Jenkinson will be responsible for supporting Metrion’s growing client base across the US, guiding projects, and navigating key milestones. He has a strong background in drug discovery and secondary pharmacology, including management of drug discovery programs across multiple therapeutic areas and stages, ranging from target identification to the nomination of candidates for preclinical development.

Jenkinson has spent over 25 years in leadership positions driving drug discovery projects for GSK and Tanabe Research Laboratories. He joins Metrion from Pfizer where, as senior director, he established, developed, and led the secondary pharmacology and high throughput screening team. Jenkinson was also previously co-chair of the IQ DruSafe Secondary Pharmacology working group and a member of the FDA’s HESI Pro-Arrhythmia group.

Andy Southan, chief executive, Metrion Biosciences, said: “We are very pleased to welcome Steve to the Metrion team. His background in both drug discovery and safety pharmacology will be pivotal in supporting our clients in the US, enhancing Metrion’s scientific leadership in this key territory.”